ABSTRACT

Anastrozole is a selective non-steroidal aromatase inhibitor and is the first drug approved by FDA in adjuvant hormonal therapy. Anastrozole was proved superior to tamoxifen for the treatment of hormoneresponsive breast cancer. In this review, we have highlighted the profile of this drug including its pharmacodynamics, pharmacokinetics, drug interactions, clinical studies and side effects.